Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL73101 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL2235362 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL9125740 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL10477646 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL3388434 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL2544645 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL8806048 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL11131940 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL11882611 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL2345211 | 0.98 | ALDH1A1 (0.68) | ALDH1A1CA4HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-3837273-A1 | IMPROVED PROTEIN RECOVERY | Bristol-Myers Squibb Company (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210171573-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-10 | — | — | US | claimed |
| WO-2020036903-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-20 | — | — | WO | claimed |
| CN-109659537-A | Citrate assists Fluorin doped ternary nano piece/polypyrrole preparation method and product and application | 上海纳米技术及应用国家工程研究中心有限公司 | 2019-04-19 | — | — | CN | claimed |
| EP-1541129-A1 | Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid | Cimex AG (CH) | 2005-06-15 | — | — | EP | claimed |
| US-20030143259-A1 | For therapy of infections of the eye and surrounding tissues | SUN PHARMACEUTICAL INDUSTRIES, INC | 2003-07-31 | — | — | US | claimed |
| EP-4720683-A1 | A BLOOD GENE SCORE TO PROGNOSE CHRONIC LUNG ALLOGRAFT DYSFUNCTION | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4649088-A1 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4519316-A1 | NEW FORMULATION OF ANTI VISTA ANTIBODY | PIERRE FABRE MEDICAMENT (FR) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024246340-A1 | A BLOOD GENE SCORE TO PROGNOSE CHRONIC LUNG ALLOGRAFT DYSFUNCTION | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-05 | — | — | WO | disclosed |
| EP-3616721-B1 | BLOOD PURIFICATION BY ALKALINIZING AGENT | UNIV TOHOKU (JP) | 2024-12-04 | — | — | EP | disclosed |
| US-20240277839-A1 | HIGH CONCENTRATION FORMULATION AND USES THEREOF | CSL LIMITED AND CSL INNOVATION PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| WO-1989004177-A1 | GAMMA INTERFERON FORMULATION | GENENTECH, INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0284249-A1 | Lyophilized lymphokine composition | INTERFERON SCIENCES, INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4675184-A | VIRICIDES | 501 Sunstar Kabushiki Kaisha (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0080879-B1 | PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON IN STABLE STATE | SUNSTAR KABUSHIKI KAISHA (JP) | 1986-10-01 | — | — | EP | disclosed |
| US-4605555-A | INTERFERON, POLYHYDRIC SUGAR ALCOHOL, ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| US-4605556-A | APPLYING INTERFERON, POLYHYDRIC SUGAR ALCOHOL, AND ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0080879-A2 | Pharmaceutical composition containing interferon in stable state | SUNSTAR KABUSHIKI KAISHA (JP) | 1983-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143259-A1 | For therapy of infections of the eye and surrounding tissues | AZI2, MALT1, PDE6D | MEN1 2597/4885ALDH1A1 1506/4885CA4 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.